The partnership will match Sanofi's money with Harvard's brains in pursuit of new therapies and diagnostics for the three key research arenas. Harvard's Office of Technology Development will bird-dog various projects Sanofi may be interested in, and the pharma giant will host an annual soiree with university researchers to bolster the relationship.
For Sanofi, the pact gives its scientists a chance to work more closely with researchers who have been at the forefront of biomedical research in the U.S. The deal follows a pact that Pfizer
"This collaboration exemplifies Harvard's commitment to creatively partner with industry in ways that we hope will push the boundaries of translational science, and advance our mandate of serving the public interest by making the fruits of our research available to society," says Steven Hyman MD, provost of Harvard University.
Google and Pfizer are Motley Fool Inside Value picks. Google is a Motley Fool Rule Breakers selection. The Fool owns shares of Google, International Business Machines, and Oracle. Try any of our Foolish newsletter services free for 30 days. True to its name, The Motley Fool is made up of a motley assortment of writers and analysts, each with a unique perspective; sometimes we agree, sometimes we disagree, but we all believe in the power of learning from each other through our Foolish community. The Motley Fool has a disclosure policy.